8-K current report · filed Nov 10, 2026

Electromed, Inc. (ELMD) 8-K Current Report: November 10, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2ELMD overview

Short answer

Electromed, Inc. (ELMD) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Fiscal first-quarter results announced for period ended September 30, 2026.

Electromed, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal first-quarter results announced for period ended September 30, 2026
  • Press release furnished as Exhibit 99.1, containing the substantive financial results
  • Results announcement provides the latest operating update for Electromed investors

Item 7.01 · Regulation FD Disclosure

  • Updated investor presentation furnished as Exhibit 99.2
  • Presentation intended for investor and analyst meetings
  • Potential market relevance limited to management’s latest investor messaging and outlook

Item EX-99.1 · Exhibit EX-99.1

  • Q1 FY2027 revenue $18.7M, up 10.6%, marking the 16th consecutive quarter of year-over-year growth
  • Direct homecare revenue rose 17.6% to $17.5M, supported by 63 sales representatives and $1.109M annualized revenue per representative
  • Operating income increased 30.7% to $3.5M, with operating margin expanding to 18.7% from 15.8%
  • Gross margin reached 80.0%, while net income rose 29.3% to $2.8M, or $0.32 diluted EPS
  • Share repurchases totaled $4.3M, reducing shares outstanding to 8.24M while leaving Electromed debt-free with $15.9M cash

Item EX-99.2 · Exhibit EX-99.2

  • Investor presentation highlights TTM revenue $75.6M, operating income $14.7M, cash $15.9M, and zero debt as of September 30, 2026
  • Q1 FY2027 revenue rose to $18.7M from $16.9M, while diluted EPS increased to $0.32 from $0.25
  • Q1 gross margin expanded to 80.0% from 78.1%, supporting operating margin growth to 18.7% from 15.8%
  • Bronchiectasis penetration remains low at approximately 16%, underpinning management’s estimated $3.1B HFCWO opportunity
  • Growth priorities include sales-force expansion, payer coverage, pediatric and hospital adjacencies, and potential acquisitions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Electromed, Inc. 8-K filings

Get the next ELMD 8-K as it lands

Follow ELMD for push alerts, or ask the research agent what this filing means.